MPs Caution UK Agreements with Donald Trump are 'Flimsy'.

Ministers and senior MPs have raised concerns that the United Kingdom's series of deals with Washington are "fundamentally unstable." This comes after revelations that a so-called "milestone" deal on medicines, which commits to zero tariffs in exchange for the NHS increasing its costs, lacks any underlying contract beyond limited headline terms published in government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, is still an "statement of intent" without detailed provisions. It has been highlighted that the official announcements from the UK and US governments describe the deal in divergent terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the expectation for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has promised concessions to increase medicine costs in return for nothing more than a verbal promise from President Trump," said David Henig, a trade policy analyst. "We know he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Concerns have been intensified by Washington's recent decision to suspend the high-value digital accord, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US cited a failure to advance from the UK on lowering trade barriers as the reason for the pause.

Additionally, concessions promised for British farmers as part of an May trade agreement have not been formally signed off by the US, despite a imminent January deadline. "We have been informed that that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have expressed concerns that the government's US-UK accords are flimsy and unreliable. One minister described the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, chair of the health select committee, stated: "Perhaps most shocking than Trump's temper tantrums is the UK government's credulous faith that his administration is a good faith actor. The NHS is not a bargaining chip."

A Mixed Picture of Success and Setback

Officials have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source indicated the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that volatility is a feature of dealing with the current US leadership. However, they contend that the UK has secured concrete outcomes for businesses, such as lower steel tariffs compared to other nations. "Our achievement of 25% steel tariffs, which is more favorable than the rate for the rest of the world, is a concrete advantage," one official said.

However, issues have surfaced in enacting the initial US-UK accord. Promised reciprocal agricultural allowances have failed to be approved, and the commitment to "reduce steel tariffs to zero" has is still pending, with tariffs fixed at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.